Screener
Alnylam Pharmaceuticals ALNY Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
FAQ
- What is Alnylam Pharmaceuticals's return on equity?
- Alnylam Pharmaceuticals (ALNY) reported return on equity of 91.4% in Q2 2026.
- What is the long-term trend for Alnylam Pharmaceuticals's return on equity?
- Over 2 years (2020 to 2025), Alnylam Pharmaceuticals's return on equity has grown at a -3.6% compound annual growth rate (CAGR), from -69.9% to 65%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Alnylam Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude